Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Vagus Nerve Preservation and Chronic Cough in Non-small Cell Lung Cancer Surgery

24 de outubro de 2022 atualizado por: Kwhanmien Kim, Seoul National University Bundang Hospital

Prospective Randomized Controlled Study on the Effects of Vagus Nerve Pulmonary Branch Preservation During Video-assisted Thoracic Surgery Lobectomy in Non-small Cell Lung Cancer: Can it Decrease Postoperative Cough and Pulmonary Complications

Lung cancer is the leading cause of cancer death worldwide. Surgical resection is the main treatment for resectable non-small-cell lung cancer (NSCLC), and lobectomy with systemic mediastinal lymph node dissection is the standard surgical method. However, a significant number of patients experience postoperative chronic cough; it is observed in about 60% of patients during the first year of outpatient clinic follow-up, and persistently lasts in about 24.7-50% during the 5 year follow-up period.

Several studies showed the association between vagus nerve and chronic cough. The bronchopulmonary vagal afferent C-fibers are responsible for cough, chest tightness and reflex bronchoconstrictions. It is expected that during the mediastinal lymph node dissection, the inevitable injuries to the pulmonary branch of vagus nerve is largely responsible for development of chronic cough. In other words, preservation of pulmonary branch of vagus nerve may reduce the incidence of chronic cough and relevant detrimental effects on quality of life.

Therefore, this prospective, randomized and controlled clinical study, aims to evaluate the effect of vagus nerve preservation on postoperative chronic cough in patients undergoing lobectomy with mediastinal lymph node dissection. In addition, the feasibility and oncologic safety of preserving pulmonary branch of vagus nerve during mediastinal lymph node dissection with minimally invasive surgery compared with conventional mediastinal lymph node dissection with minimally invasive surgery will also be investigated.

This trial will provide a new basis for oncologically feasible, safe and effective new surgical technique for mediastinal lymph node dissection in patients with early lung cancer undergoing minimally invasive surgery. Furthermore, the preventive effect of vagus nerve preservation on incidence of chronic cough will be objectively be proven and thus help to broaden the current knowledge of the role of vagus nerve and postoperative chronic cough.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Antecipado)

214

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Kwhanmien Kim, MD. PhD
  • Número de telefone: +82-31-787-7130
  • E-mail: kmkim0070@snubh.org

Locais de estudo

    • Bundang
      • Seongnam-si, Bundang, Republica da Coréia, 13620
        • Recrutamento
        • Seoul National University
        • Contato:
          • Beatrice C Shih, MD
          • Número de telefone: 821091094533
          • E-mail: 82430@snubh.org
        • Investigador principal:
          • Kwhanmien Kim, MD.PhD.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Subjects clearly understand the purpose of the study, are willing and able to comply with the requirements to complete the study, and can sign the informed consent.
  2. Clinically suspicious of non-small cell lung cancer or tissue confirmed preoperatively
  3. Clinical stage T1-3/N0-1/M0
  4. Preoperative ECOG performance status 0-1
  5. Preoperative ASA class I-III
  6. Preoperative pulmonary function test FEV1 ≥ 60%, DLCO ≥ 60%
  7. Patients expected to achieve R0 (complete resection) via simple lobectomy and mediastinal lymph node dissection

Exclusion Criteria:

  1. Patients who smoked within 2 weeks prior to operation
  2. Patients who received antitussives and expectorants 2 weeks prior to operation
  3. Patients who are pregnant or breast feeding
  4. Patients with severe or uncontrolled psychological disorders
  5. Patients with severe pulmonary adhesion
  6. Patients who are ineligible for minimally invasive surgery; thoracotomy conversion
  7. Patients diagnosed with other malignancies within 2 years prior to operation
  8. Patients who received chemotherapy or radiotherapy within 6 months prior to operation
  9. Patients suspicious of clinical N2 or received neoadjuvant therapy prior to operation
  10. Patients with cough-related diseases; COPD, asthma, ILD, GERD
  11. Patients suspicious of lymph node metastasis/invasion around vagus nerve during the preoperative clinical staging evaluation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Pulmonary branch of vagus nerve preserved
Pulmonary branch of vagus nerve is preserved during the mediastinal lymph node dissection using minimally invasive surgery
During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
Experimental: Pulmonary branch of vagus nerve not-preserved
Pulmonary branch of vagus nerve is not preserved during the mediastinal lymph node dissection using minimally invasive surgery
During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Qualitative measurement of postoperative cough
Prazo: Preoperative day
Cough Visual Analog Scale (VAS) will be used for survey. The Cough VAS is a numeric scale from 0-10 scale, with 0 indicating that patient experiences no distress from cough and 10 indicating severe distress from cough.
Preoperative day
Qualitative measurement of postoperative cough
Prazo: Postoperative day (discharge day, an average of 1 week)
Cough Visual Analog Scale (VAS) will be used for survey. The Cough VAS is a numeric scale from 0-10 scale, with 0 indicating that patient experiences no distress from cough and 10 indicating severe distress from cough.
Postoperative day (discharge day, an average of 1 week)
Qualitative measurement of postoperative cough
Prazo: Postoperative 1 month follow up at outpatient clinic
Cough Visual Analog Scale (VAS) will be used for survey. The Cough VAS is a numeric scale from 0-10 scale, with 0 indicating that patient experiences no distress from cough and 10 indicating severe distress from cough.
Postoperative 1 month follow up at outpatient clinic
Qualitative measurement of postoperative cough
Prazo: Postoperative 2 month follow up at outpatient clinic
Cough Visual Analog Scale (VAS) will be used for survey. The Cough VAS is a numeric scale from 0-10 scale, with 0 indicating that patient experiences no distress from cough and 10 indicating severe distress from cough.
Postoperative 2 month follow up at outpatient clinic
Qualitative measurement of postoperative cough
Prazo: Postoperative 6 month follow up at outpatient clinic
Cough Visual Analog Scale (VAS) will be used for survey. The Cough VAS is a numeric scale from 0-10 scale, with 0 indicating that patient experiences no distress from cough and 10 indicating severe distress from cough.
Postoperative 6 month follow up at outpatient clinic
Qualitative measurement of postoperative cough
Prazo: Postoperative 12 month follow up at outpatient clinic
Cough Visual Analog Scale (VAS) will be used for survey. The Cough VAS is a numeric scale from 0-10 scale, with 0 indicating that patient experiences no distress from cough and 10 indicating severe distress from cough.
Postoperative 12 month follow up at outpatient clinic
Quantitative measurement of postoperative cough
Prazo: Preoperative day
The Korean version of the Leicester Cough Questionnaire will be used for survey. Comparison of preoperative and and postoperative change in objective cough frequency and quality of life among patients using the Leicester Cough Questionnaire, which is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Preoperative day
Quantitative measurement of postoperative cough
Prazo: Postoperative day (discharge day, an average of 1 week)
The Korean version of the Leicester Cough Questionnaire will be used for survey. Comparison of preoperative and and postoperative change in objective cough frequency and quality of life among patients using the Leicester Cough Questionnaire, which is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Postoperative day (discharge day, an average of 1 week)
Quantitative measurement of postoperative cough
Prazo: Postoperative 1 month follow up at outpatient clinic
The Korean version of the Leicester Cough Questionnaire will be used for survey. Comparison of preoperative and and postoperative change in objective cough frequency and quality of life among patients using the Leicester Cough Questionnaire, which is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Postoperative 1 month follow up at outpatient clinic
Quantitative measurement of postoperative cough
Prazo: Postoperative 2 month follow up at outpatient clinic
The Korean version of the Leicester Cough Questionnaire will be used for survey. Comparison of preoperative and and postoperative change in objective cough frequency and quality of life among patients using the Leicester Cough Questionnaire, which is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Postoperative 2 month follow up at outpatient clinic
Quantitative measurement of postoperative cough
Prazo: Postoperative 6 month follow up at outpatient clinic
The Korean version of the Leicester Cough Questionnaire will be used for survey. Comparison of preoperative and and postoperative change in objective cough frequency and quality of life among patients using the Leicester Cough Questionnaire, which is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Postoperative 6 month follow up at outpatient clinic
Quantitative measurement of postoperative cough
Prazo: Postoperative 12 month follow up at outpatient clinic
The Korean version of the Leicester Cough Questionnaire will be used for survey. Comparison of preoperative and and postoperative change in objective cough frequency and quality of life among patients using the Leicester Cough Questionnaire, which is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Postoperative 12 month follow up at outpatient clinic

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Serum TRPA1, TRPV1, bradykinin, PGE2 measurements
Prazo: Preoperative day
Measurement of TRPA1 (ng/mL), TRPV1 (ng/mL), bradykinin (pg/mL), PGE2 (pg/mL) (released from C-fibers) via enzyme-linked immunosorbent assay (ELISA) test to quantitatively measure the injures of the vagus nerve during the mediastinal lymph node dissection.
Preoperative day
Serum TRPA1, TRPV1, bradykinin, PGE2 measurements
Prazo: Postoperative 1 day
Measurement of TRPA1 (ng/mL), TRPV1 (ng/mL), bradykinin (pg/mL), PGE2 (pg/mL) (released from C-fibers) via enzyme-linked immunosorbent assay (ELISA) test to quantitatively measure the injures of the vagus nerve during the mediastinal lymph node dissection.
Postoperative 1 day
Serum TRPA1, TRPV1, bradykinin, PGE2 measurements
Prazo: Postoperative 2 month follow up at outpatient clinic
Measurement of TRPA1 (ng/mL), TRPV1 (ng/mL), bradykinin (pg/mL), PGE2 (pg/mL) (released from C-fibers) via enzyme-linked immunosorbent assay (ELISA) test to quantitatively measure the injures of the vagus nerve during the mediastinal lymph node dissection.
Postoperative 2 month follow up at outpatient clinic
Pulmonary function test
Prazo: Preoperative day
Routine PFT (FEV1%, FEV1/FVC%) check to evaluate the effects of vagus nerve preservation in pulmonary function
Preoperative day
Pulmonary function test
Prazo: Postoperative 1 month follow up at outpatient clinic
Routine PFT (FEV1%, FEV1/FVC%) check to evaluate the effects of vagus nerve preservation in pulmonary function
Postoperative 1 month follow up at outpatient clinic
Pulmonary function test
Prazo: Postoperative 2 month follow up at outpatient clinic
Routine PFT (FEV1%, FEV1/FVC%) check to evaluate the effects of vagus nerve preservation in pulmonary function
Postoperative 2 month follow up at outpatient clinic
Pulmonary function test
Prazo: Postoperative 6 month follow up at outpatient clinic
Routine PFT (FEV1%, FEV1/FVC%) check to evaluate the effects of vagus nerve preservation in pulmonary function
Postoperative 6 month follow up at outpatient clinic
Pulmonary function test
Prazo: Postoperative 12 month follow up at outpatient clinic
Routine PFT (FEV1%, FEV1/FVC%) check to evaluate the effects of vagus nerve preservation in pulmonary function
Postoperative 12 month follow up at outpatient clinic
Incidence of postoperative pulmonary complications, hospital stay and readmission, ICU care
Prazo: from admission for operation to until the date of first documented postoperative complication or readmission, whichever came first), assessed up to 30 days
from admission for operation to until the date of first documented postoperative complication or readmission, whichever came first), assessed up to 30 days
Histopathologic review of the total number of mediastinal lymph node dissected
Prazo: through study completion, an average of 1 year
Total number of dissected mediastinal lymph nodes and metastatic lymph nodes will be analyzed. Patient's preoperative clinical N stage and pathologic N stage will be compared; if pathologic N stage is higher than that of the clinical N stage, it will be considered as nodal upstaging.
through study completion, an average of 1 year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Kwhanmien Kim, MD. PhD, Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de julho de 2021

Conclusão Primária (Antecipado)

30 de junho de 2023

Conclusão do estudo (Antecipado)

30 de junho de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

23 de maio de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de junho de 2021

Primeira postagem (Real)

11 de junho de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

26 de outubro de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de outubro de 2022

Última verificação

1 de outubro de 2022

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever